Relapsed or Refractory B-cell Non-Hodgkin LymphomaPhase 1TARZANNCT06824701
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Phase 1 study testing Zanubrutinib, Rituximab and Obinutuzumab in people with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, run by University of Utah at 1 site in United States.
Trial summary
The purpose of this clinical trial is to learn if the study drug Tazemetostat combined with Zanubrutinib and anti-CD20 monoclonal antibody is safe and effective in treating patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- What is being tested?
- Zanubrutinib, Rituximab and Obinutuzumab
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteUnited States
- Study dates
- 12 Sep 2025to Jan 2033
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject aged ≥ 18 years.
- Eligible histologies include MCL, MZL (including splenic, nodal, and extranodal sub-types), and WM who received at least one line of prior systemic therapy and FL who received at least two prior lines of systemic therapy
- Measurable disease: at least one lesion >1.5 cm in longest diameter or 1 extranodal lesion >1 cm in the longest diameter.
- --Note: For MZL, isolated splenomegaly and involvement of any biopsy proven extranodal site is considered measurable for this study. For MCL, clonal lymphocyte measured by flow cytometry is considered measurable. For WM, serum IgM level >0.5 g/dL is considered measurable.
- Patients must have an indication for treatment.
- For R/R FL: active disease requiring treatment
Show all 62Show fewer
- For R/R MCL: active disease requiring treatment
- For R/R MZL: active disease requiring treatment
- For R/R WM: Meeting at least 1 criterion for treatment according to consensus panel criteria from the Seventh International Workshop on Waldenstrom's Macroglobulinemia68
- Recurrent fever, night sweats, weight loss, fatigue
- Hyper viscosity
- Lymphadenopathy which is either symptomatic or bulky (≥ 5 cm in maximum diameter)
- Symptomatic hepatomegaly and/or splenomegaly
- Symptomatic organomegaly and/or organ or tissue infiltration
- Peripheral neuropathy due to WM
- Symptomatic cryoglobulinemia
- Cold agglutinin anemia
- Immune hemolytic anemia and/or thrombocytopenia related to WM
- Nephropathy related to WM
- Amyloidosis related to WM
- Hemoglobin <10 g/dL
- Platelet count <100,000/mm3
- ECOG Performance Status ≤ 2.
- Adequate organ function as defined as:
- Hematologic:
- Absolute neutrophil count (ANC) ≥750 cells/mm3 (≥0.75 x 10^9/L) independent of G-CSF support
- Platelet count ≥75,000 cells/mm^3 (≥75 x 10^9/L) independent of transfusion support.
- Hepatic:
- Total Bilirubin ≤1.5 x upper limit of normal (ULN) or ≤3 x ULN with document liver involvement and/ or Gilbert's disease.
- AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN ----Subjects with liver involvement will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.
- Renal:
- Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula:
- Adequate coagulation, defined as activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) and prothrombin (PT) or (international normalized ratio (INR) not greater than 1.5 x ULN.
- Life expectancy of >3 months, in the opinion of the investigator
- For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
- Women < 50 years of age:
- Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and
- Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or
- Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
- Women ≥ 50 years of age:
- Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or
- Had radiation-induced menopause with last menses >1 year ago; or
- Had chemotherapy-induced menopause with last menses >1 year ago; or
- Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).
- Female subjects of childbearing potential and male subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception and lactation requirements as described in Section 5.3.1 and 5.3.2.
- Subjects must agree to not breastfeed while on treatment or within 1 week of the last dose of tazemetostat or 2 weeks of zanubrutinib.
- Ability to swallow oral tablets
- Patients or their legal representatives must be able to read, understand, and provide informed consent to participate in the trial.
- Willing and capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
- Time between prior anticancer therapy and first dose of tazemetostat as below:
- Cytotoxic chemotherapy - At least 21 days
- Non-cytotoxic chemotherapy (e.g., small molecule inhibitor) - At least 14 days
- Monoclonal antibody(ies) - At least 28 days
- Radiotherapy
- At least 14 days from local site radiation therapy
- At least 6 weeks from prior radioisotope therapy
- At least 12 weeks from 50% pelvic or total body irradiation
- High-dose therapy with autologous hematopoietic cell infusion - At least 60 days
- CART cell therapy - At least 60 days
- Moderate CYP3A inhibitors - At least 3 elimination half-lives
- Moderate CYP3A inducers - At least 14 days
- Strong CYP3A inducers or inhibitors - At least 14 days ----Note: Must be able to obtain zanubrutinib and anti-CD20 mAb commercially
Who cannot join
- Prior exposure to tazemetostat or other inhibitor(s) of EZH2
- Any prior history of myeloid malignancies including MDS/AML or MPN
- Any prior history of T-LBL, T-ALL, or B-ALL
- Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drugs
- Major surgery within 4 weeks prior to enrollment
- Known history of bleeding diathesis or active bleeding
Show all 28Show fewer
- Known history of stroke or intracranial hemorrhage within 6 months of enrollment
- Significant cardiovascular disease defined as:
- unstable angina or acute coronary syndrome within the past 2 months prior to study enrollment
- history of myocardial infarction within 3 months prior to study enrollment or documented LVEF by any method of ≤ 40% in the 12 months prior to study enrollment --≥ Grade 3 NYHA functional classification system of heart failure, uncontrolled or symptomatic arrhythmias
- Significant liver disease (>Child Pugh Class A)
- Patients with CNS involvement
- Prolongation of the QT interval corrected for heart rate (QTcF) > 480 msec. QTcF is calculated using Fridericia's Formula (QTcF): QTcF = QT/(RR0.33).
- Correction of suspected drug induced QTcF prolongation can be attempted at the investigator's discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation.
- Correction for underlying bundle branch block (BBB) allowed. ---Note: Patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker
- Patients who have tested positive for Human Immunodeficiency Virus (HIV)
- Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection based on criteria below:
- Hepatitis B virus (HBV): Patients with positive hepatitis B surface antigen (HBsAg) are excluded. Patients with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require hepatitis B polymerase chain reaction (PCR) evaluation before enrollment. Patients who are HBV DNA PCR positive will be excluded. Patients with positive anti-HBc and negative HBV DNA should be on prophylactic nucleo(t)side analogue therapy to prevent reactivation with serial HBV DNA PCR monitoring (see the section on "General guidance for hepatic monitoring")
- Hepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before enrollment. Patients who are hepatitis C RNA positive will be excluded.
- Known Cytomegalovirus (CMV) infection.
- Evidence of other clinically significant uncontrolled condition(s) including but not limited to, uncontrolled systemic bacterial, viral, fungal, or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which in the opinion of the investigator and medical monitor may pose a risk for patient participation. Screening for chronic conditions is not required.
- Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP]) for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts.
- Active second malignancy unless in remission and with life expectancy > 2 years.
- Patients requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist.
- Receipt of live virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
- Have a known hypersensitivity to any of the excipients of tazemetostat.
- Subjects taking medications that are known strong CYP3A4 inducers or inhibitors and cannot come off the medication.
- Subjects taking medications that are known moderate CYP3A inducers and cannot come off the medication.
Trial locations and contacts
1 site in 1 country.
United States1 site
Huntsman Cancer Institute at University of Uta
Salt Lake City, Utah, 84112
About this study
Official title: A Phase 1b Study of Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphomas (TARZAN Trial)
The purpose of this clinical trial is to learn if the study drug Tazemetostat combined with Zanubrutinib and anti-CD20 monoclonal antibody is safe and effective in treating patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
- Being tested
- Zanubrutinib, Rituximab, Obinutuzumab
- Medical subject headings
- Recurrence, Lymphoma, B-Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ZanubrutinibDrug
Also called Brukinsa
Zanubrutinib will be self-administered BID as an oral treatment on a 28-day cycle.
RituximabDrug
Also called Ruxience, Rituxan
Rituximab or a biosimilar will be administered intravenously per standard of care.
ObinutuzumabDrug
Also called Gazyva
Obinutuzumab will be administered intravenously on days 1, 8, 15 of cycle 1 and then day 1 of cycles 2 to 12.
| Study group | Role | What they receive |
|---|---|---|
| Treatment: All Patients | Experimental | The study will investigate the effectiveness of Tazemetostat in combination with Zanubrutinib and anti-CD20 monoclonal antibody Receives: Drug: Zanubrutinib; Drug: Rituximab; Drug: Obinutuzumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maximum Tolerated Dose (MTD) of tazemetostat in combination with zanubrutinib and anti-CD20 mAb
To determine the MTD of tazemetostat in with zanubrutinib and anti-CD20 mAb. MTD is the highest dose where 0 of the first 3 or 1 of 6 patients had a dose-limiting Toxicity (DLT) during Cycle 1 of tazemetostat treatment.
This will report the number of patients with DLTs at Dose Level (DL)-1, DL1, and DL2. A DLT is:
A Grade ≥ 3 non-hematologic toxicity lasting >3 days EXCEPT:
- Alopecia
- Grade 3 fatigue, asthenia, anorexia, constipation, nausea, vomiting, or diarrhea not requiring tube feeding, total parenteral nutrition, or hospitalization
- Grade 3 or 4 tumor lysis syndrome (resolved ≥7 days) or electrolyte abnormalities (resolved to < Grade 2 in <72 hours)
- Grade 3 alkaline phosphatase, gamma-glutamyl transferase, amylase, or lipase elevation < 72 hours.
Any of these hematologic toxicities:
- Grade 4 neutropenia, febrile neutropenia, or thrombocytopenia
- Grade 5 hematologic toxicity
Dose delay due to toxicity > 28 days
Measured: 2 years
Secondary outcomes (7)
Overall response rate (ORR) rate at Cycle 7 Day 1 (C7D1)
To evaluate the ORR at C7D1. ORR is the proportion of patients who had a treatment outcome of Partial Response (PR), Very Good Partial Response (VGPR), or Complete Response (CR).
CR is the absence of serum monoclonal Immunoglobulin M (IgM) protein by immunofixation, normal serum IgM level, resolution of extramedullary disease, and normal bone marrow aspirate and trephine biopsy.
VGPR is detectable monoclonal IgM protein, ≥90% reduction in serum IgM level, complete resolution of extramedullary disease, and no new signs of active disease.
PR is detectable Monoclonal IgM protein, ≥50% but < 90% reduction in serum IgM, reduction in extramedullary disease, and no new sign of active disease.
These are based on the response criteria for Waldenstrom Macroglobulinemia (WM) developed by the International Workshop on WM (IWWM), updated in the sixth IWWM.
ORR indicates that treatment was effective. This outcome measure will report the proportion of patients who achieve ORR at C7D1.
Measured: 8 months
Very Good Partial Response (VGPR) Rate at Cycle 7 Day 1 (C7D1)
To evaluate the Very Good Partial Response (VGPR) rate at Cycle 7 Day 1 (C7D1). VGPR is a treatment outcome for t B-cell non-Hodgkin lymphomas characterized by detectable monoclonal IgM protein, ≥90% reduction in serum IgM level from baseline, a complete resolution of extramedullary disease (ie, lymphadenopathy/splenomegaly if present at baseline), and no new signs or symptoms of active disease.
The response assessment will be based on the consensus-based uniform response criteria for Waldenstrom Macroglobulinemia (WM) developed by the International Workshop on Waldenstrom's Macroglobulinemia (IWWM), updated in the sixth IWWM.
VGPR is used to indicate that the treatment has been highly effective, leading to substantial but not complete remission. This outcome measure will report the proportion of patients who achieve VGPR at C7D1.
Measured: 8 months
Median Duration of Response (DOR)
To evaluate the Duration of Response (DOR) in participants who achieve response. DOR is defined as for patients who achieve response, the time from initial response to the time of death or progression, whichever occurs first. Participants who still respond at their last follow-up will be censored at that time.
This outcome measure will report the median DOR and corresponding 95% confidence interval.
Measured: 7 years
Median Progression-Free Survival (PFS)
To evaluate median Progression-Free Survival (PFS) from treatment initiation. PFS is defined as the time from treatment initiation to the time of disease progression or death. Patients who are alive and progression-free will be censored at their last follow-up time. Patients who start a subsequent anticancer therapy will be censored at their last follow-up prior to the start of anticancer therapy.
This outcome measure will report the median PFS with the corresponding 95% confidence interval.
Measured: 2 years
Progression-Free Survival (PFS) at two years after treatment initiation.
To evaluate Progression-Free Survival (PFS) at two years after treatment initiation. PFS is defined as the time from treatment initiation to the time of disease progression or death. Patients who are alive and progression-free will be censored at their last follow-up time. Patients who start a subsequent anticancer therapy will be censored at their last follow-up prior to the start of anticancer therapy.
This outcome will report the proportion of patients who remain free from disease progression two years after starting treatment.
Measured: 2 years
Median Overall Survival (OS)
To evaluate median overall survival (OS) from treatment initiation. OS is defined as the time from treatment initiation to the time of death, with participants who are alive at their last follow-up time being censored at that time.
This outcome measure will report the median OS with the corresponding 95% confidence interval.
Measured: 2 years
Overall Survival (OS) at two years after treatment initiation.
To evaluate Overall Survival (OS) at two years after treatment initiation. OS is defined as the time from treatment initiation to the time of death, with participants who are alive at their last follow-up time being censored at that time.
This outcome will report the proportion of participants who are still alive two years following the start of their treatment.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Feb 2025
- Study start12 Sep 2025
- Primary completionJan 2032 (estimated)
- Study completionJan 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Relapsed or Refractory B-cell Non-Hodgkin LymphomaStudies of the same condition, open and under way.
- More trials run by University of UtahThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- As of amendment 31MAR2026, emerging safety data shows additional cases of secondary hematologic malignancies. Cases continue to be reviewed and a causal relationship has not yet been established. However, based on this data, Ispen, manufacturer of tazemetostat, made the decision to discontinue all treatment with tazemetostat.
- Masking
- None (open label)
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Utah
- Sponsor type
- University, hospital or other
- Collaborators
- Ipsen
- Responsible party
- Sponsor
- Investigators
- Narendranath Epperla, MD, MS, FACP, Principal investigator, Huntsman Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06824701
- Sponsor's protocol ID
- HCI183680
- Acronym
- TARZAN
- Status last verified
- Apr 2026
- First submitted
- 16 Jan 2025
- Last updated
- 30 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1b Study of Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphomas (TARZAN Trial)
- ClinicalTrials.gov ID
- NCT06824701
- Acronym / sponsor ID
- TARZAN / HCI183680
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- University of UtahUniversity, hospital or other
- Collaborators
- Ipsen
- Study start
- 12 Sep 2025 (actual)
- Primary completion
- Jan 2032 (estimated)
- Study completion
- Jan 2033 (estimated)
- First posted
- 13 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this clinical trial is to learn if the study drug Tazemetostat combined with Zanubrutinib and anti-CD20 monoclonal antibody is safe and effective in treating patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- As of amendment 31MAR2026, emerging safety data shows additional cases of secondary hematologic malignancies. Cases continue to be reviewed and a causal relationship has not yet been established. However, based on this data, Ispen, manufacturer of tazemetostat, made the decision to discontinue all treatment with tazemetostat.
| Arm | Type | Receives |
|---|---|---|
| Treatment: All Patients | Experimental | Drug: Zanubrutinib, Drug: Rituximab, Drug: ObinutuzumabThe study will investigate the effectiveness of Tazemetostat in combination with Zanubrutinib and anti-CD20 monoclonal antibody |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (62 listed)
- Subject aged ≥ 18 years.
- Eligible histologies include MCL, MZL (including splenic, nodal, and extranodal sub-types), and WM who received at least one line of prior systemic therapy and FL who received at least two prior lines of systemic therapy
- Measurable disease: at least one lesion >1.5 cm in longest diameter or 1 extranodal lesion >1 cm in the longest diameter.
- --Note: For MZL, isolated splenomegaly and involvement of any biopsy proven extranodal site is considered measurable for this study. For MCL, clonal lymphocyte measured by flow cytometry is considered measurable. For WM, serum IgM level >0.5 g/dL is considered measurable.
- Patients must have an indication for treatment.
Key exclusion criteria (28 listed)
- Prior exposure to tazemetostat or other inhibitor(s) of EZH2
- Any prior history of myeloid malignancies including MDS/AML or MPN
- Any prior history of T-LBL, T-ALL, or B-ALL
- Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drugs
- Major surgery within 4 weeks prior to enrollment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ZanubrutinibAlso: BrukinsaZanubrutinib will be self-administered BID as an oral treatment on a 28-day cycle. | Drug | Treatment: All Patients |
| RituximabAlso: Ruxience, RituxanRituximab or a biosimilar will be administered intravenously per standard of care. | Drug | Treatment: All Patients |
| ObinutuzumabAlso: GazyvaObinutuzumab will be administered intravenously on days 1, 8, 15 of cycle 1 and then day 1 of cycles 2 to 12. | Drug | Treatment: All Patients |
Primary outcome
Maximum Tolerated Dose (MTD) of tazemetostat in combination with zanubrutinib and anti-CD20 mAb
Time frame: 2 years
To determine the MTD of tazemetostat in with zanubrutinib and anti-CD20 mAb. MTD is the highest dose where 0 of the first 3 or 1 of 6 patients had a dose-limiting Toxicity (DLT) during Cycle 1 of tazemetostat treatment. This will report the number of patients with DLTs at Dose Level (DL)-1, DL1, and DL2. A DLT is: A Grade ≥ 3 non-hematologic toxicity lasting >3 days EXCEPT: * Alopecia * Grade 3 fatigue, asthenia, anorexia, constipation, nausea, vomiting, or diarrhea not requiring tube feeding, total parenteral nutrition, or hospitalization * Grade 3 or 4 tumor lysis syndrome (resolved ≥7 days) or electrolyte abnormalities (resolved to < Grade 2 in <72 hours) * Grade 3 alkaline phosphatase, gamma-glutamyl transferase, amylase, or lipase elevation < 72 hours. Any of these hematologic toxicities: * Grade 4 neutropenia, febrile neutropenia, or thrombocytopenia * Grade 5 hematologic toxicity Dose delay due to toxicity > 28 days
7 secondary outcomes
Overall response rate (ORR) rate at Cycle 7 Day 1 (C7D1)
Time frame: 8 months
Very Good Partial Response (VGPR) Rate at Cycle 7 Day 1 (C7D1)
Time frame: 8 months
Median Duration of Response (DOR)
Time frame: 7 years
Median Progression-Free Survival (PFS)
Time frame: 2 years
Progression-Free Survival (PFS) at two years after treatment initiation.
Time frame: 2 years
Median Overall Survival (OS)
Time frame: 2 years
Overall Survival (OS) at two years after treatment initiation.
Time frame: 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
RecruitingPhase 2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma
RecruitingPhase 1/2
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Lymphoma, Waldenström Macroglobulinemia (WM)
Active, not recruitingPhase 1
A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma
Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Relapsed
RecruitingObservational study
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Narendranath Epperla, MD, MS, FACP principal investigator
Huntsman Cancer Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Zanubrutinib, Rituximab and Obinutuzumab in people with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, run by University of Utah at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 62 inclusion and 28 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 30 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Maximum Tolerated Dose (MTD) of tazemetostat in combination with zanubrutinib and anti-CD20 mAb (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2026; AzTrials last refreshed its copy on 8 Nov 2026.